SCHEMBL5492669

SCHEMBL5492669

[c]1[nH]c2ccccc2c1-c1cccc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALPL P05186 1/20 0.39
GAA P10253 1/20 0.39
GSK3B P49841 2/20 0.38
ADK P55263 1/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP2A6 P11509 2/20 0.38
NISCH Q9Y2I1 1/20 0.38
ALOX15 P16050 1/20 0.36
PARP1 P09874 1/20 0.35
KIF11 P52732 1/20 0.35
PTPN1 P18031 1/20 0.35
TYMP P19971 1/20 0.35
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723685 0.77 ABCG2 (0.43) KDM4EGAAGSK3BADKALDH1A1
SCHEMBL16322764 0.74 HSD17B10 (0.47) KDM4EGSK3BALDH1A1ALOX15PTPN1
SCHEMBL1257288 0.73 RAB9A (0.52) KDM4EGAAGSK3BALDH1A1ALOX15
SCHEMBL5750914 0.73 KDM4E (0.45) BCHEKDM4EALDH1A1CYP2A6HSD17B10
SCHEMBL718222 0.72 ALDH1A1 (0.41) KDM4EALPLGAAALDH1A1TSHR
SCHEMBL6609359 0.72 ALDH1A1 (0.38) GAAALDH1A1TSHRTDP1
SCHEMBL7781750 0.71 HTR2B (0.42) NISCHCYP1A2
SCHEMBL7186438 0.71 ATM (0.32) ADKALDH1A1CYP2A6KIF11HSD17B10
SCHEMBL4508938 0.71 MAOB (0.59) KDM4EGAAALDH1A1HSD17B10
SCHEMBL646330 0.70 ALDH1A1 (0.42) KDM4EALPLGAAALDH1A1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070027158-A1 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION 2007-02-01 US claimed
US-5624939-A N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders RHONE-POULENC RORER, S.A. (FR) 1997-04-29 US claimed
US-20070092488-A1 Methods of treating idiopathic pulmonary fibrosis INTERMUNE INC. (US) 2007-04-26 US disclosed
US-6545152-B1 Viricides; polymerase enzyme inhibitor PARKER HUGHES INSTITUTE 2003-04-08 US disclosed
US-3997584-A Substituted glycines and intermediates thereof SMITHKLINE CORPORATION (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027158-A1 High affinity small molecule C5a receptor modulators C3AR1, C5AR1, C5AR2 BCHE 1835/4885KDM4E 3927/4885ALPL 4647/4885
US-20070092488-A1 Methods of treating idiopathic pulmonary fibrosis IFNG, MMP1, IFNAR1 BCHE 2789/4885KDM4E 4367/4885ALPL 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.